Purple Biotech is a biotechnology business based in the US. Purple Biotech shares (PPBT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.62 – an increase of 3.97% over the previous week. Purple Biotech employs 20 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.62 |
|---|---|
| 52-week range | $2.50 - $23.20 |
| 50-day moving average | $5.05 |
| 200-day moving average | $9.71 |
| Wall St. target price | $33.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-12.13 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.62 from 2024-11-19
| 1 week (2024-11-13) | -1.50% |
|---|---|
| 1 month (2024-10-18) | -40.05% |
| 3 months (2024-08-20) | 523.96% |
| 6 months (2024-05-20) | 365.20% |
| 1 year (2023-11-20) | 162.00% |
|---|---|
| 2 years (2022-11-18) | -93.79% |
| 3 years (2021-11-19) | 81.2 |
| 5 years (2019-11-20) | 146 |
| Gross profit TTM | $-120,000 |
|---|---|
| Return on assets TTM | -29.25% |
| Return on equity TTM | -44.67% |
| Profit margin | 0% |
| Book value | $0.11 |
| Market Capitalization | $4.3 million |
TTM: trailing 12 months
We're not expecting Purple Biotech to pay a dividend over the next 12 months.
Purple Biotech's shares were split on a 1:20 basis on 16 September 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Purple Biotech shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Purple Biotech shares which in turn could have impacted Purple Biotech's share price.
Over the last 12 months, Purple Biotech's shares have ranged in value from as little as $2.5 up to $23.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Purple Biotech's is 0.384. This would suggest that Purple Biotech's shares are less volatile than average (for this exchange).
Purple Biotech Ltd. , a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.